论文部分内容阅读
柳氮磺吡啶(SASP)被广泛用于治疗炎症性肠病,已知其有效成分为5-对氨基水杨酸(5-ASA)。由于SASP副作用发生率高,作者合成了含有两个5-ASA的新药偶氮二水杨酸二钠disodium azodisalicylate(ADS),并研究比较了ADS与SASP在体内的分布。 6名健康志愿者,男性,无胃肠紊乱或腹泻史。口服单剂SASP 2.3g,3周后几服单剂ADS1g,每剂含同量5-ASA。头晚禁食至
Sulfasalazine (SASP) is widely used in the treatment of inflammatory bowel disease and its active ingredient is known as 5-aminosalicylic acid (5-ASA). Due to the high incidence of SASP side effects, the authors synthesized disodium azodisalicylate (ADS), a novel drug containing two 5-ASA, and compared the distribution of ADS and SASP in vivo. Six healthy volunteers, men, had no history of gastrointestinal disorders or diarrhea. Oral single-dose SASP 2.3g, 3 weeks after taking a single dose of ADS1g, each containing the same amount of 5-ASA. Fasting night to fast